Caplacizumab is a von Willebrand factor (vWF)-directed antibody fragment designed to inhibit the interaction between vWF and platelets.
The treatment for acquired thrombotic thrombocytopenic purpura, a rare blood disorder that causes blood clots in the small ...
According to a release issued on January 6, 2026, the Nims blood bank recorded a landmark performance in voluntary blood ...
MS NOW on MSNOpinion
Trump quadrupling up on aspirin is a metaphor for his presidency
Trump casually dismisses evidence-based recommendations as he attacks panels that makes such recommendations for the American ...
Summit Fire & EMS and Red, White & Blue Fire emergency medical crews now carry “whole blood” to administer to trauma patients ...
The Food and Drug Administration has approved Yartemlea ® (narsoplimab-wuug) for the treatment of adult and pediatric patients aged 2 years and older with hematopoietic stem cell transplant ...
Shares of WORK Medical are rising Monday after the company received manufacturing approval for one of its AI-powered products ...
FOSTER CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today ...
Oral presentation from pooled analyses of the IMerge population suggests that treatment-emergent cytopenias may reflect on-target effects associated with meaningful clinical outcomes, including ...
Sanofi’s Wayrilz approved in the EU as the first BTK inhibitor to treat immune thrombocytopeniaNovel treatment targets BTK through multi-immune ...
As donations dip after the holidays, the need for blood never stops. Discover how local donors are stepping up to save lives ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback